Current clinical guidelines regarding the monitoring of treatment in advanced lung cancer do not recommend the routine determination of biomarkers.6 To evaluate CEA and LDH levels in relation to treatment response, a retrospective follow‐up study in a large cohort of patients with advanced NSCLC receiving first‐line platinum‐based chemotherapy, was conducted. The gene discussed is CEACAM5; the disease is lung cancer.